Literature DB >> 25868531

Intranasal administration with recombinant Lactococcus lactis expressing heme oxygenase-1 reduces hyperoxia-induced lung inflammation in rat pups.

Chang-Yi Wu1, Luis G Bermúdez-Humarán, Feng Yue, Min Li, Li-Ping Zhang.   

Abstract

OBJECTIVES: To evaluate the effects of a recombinant strain of Lactococcus lactis secreting bioactive heme oxygenase-1 (LL-HO-1) in a model of hyperoxia-induced lung injury in rat pups
RESULTS: Intranasal administration with LL-HO-1 significantly reduced hyperoxia-induced lung injury as demonstrated by a decreased wet/dry ratio, myeloperoxidase activity in lung tissue, tumor necrosis factor alpha levels in bronchoalveolar lavage (BAL) fluid, and attenuated lung injury scores. Although expression of HO-1 and NADPH oxidase-1 and production of superoxide in lung tissue were not affected by LL-HO-1 treatment, HO-1 levels in nasal mucosa and interleukin-10 concentrations in BAL fluid significantly increased compared with the hyperoxia control group
CONCLUSIONS: Intranasal administration of LL-HO-1 protects against hyperoxia-induced lung damage, apparently through attenuation of inflammation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25868531     DOI: 10.1007/s10529-015-1795-3

Source DB:  PubMed          Journal:  Biotechnol Lett        ISSN: 0141-5492            Impact factor:   2.461


  2 in total

Review 1.  Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health.

Authors:  Romina Levit; Naima G Cortes-Perez; Alejandra de Moreno de Leblanc; Jade Loiseau; Anne Aucouturier; Philippe Langella; Jean Guy LeBlanc; Luis G Bermúdez-Humarán
Journal:  Gut Microbes       Date:  2022 Jan-Dec

2.  Anti-apoptosis effect of heme oxygenase-1 on lung injury after cardiopulmonary bypass.

Authors:  Wei Sheng; Haiqin Yang; Zhaozhuo Niu; Hong Yin
Journal:  J Thorac Dis       Date:  2020-04       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.